Science & Pipeline
Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis.
Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.
Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 | ApprovedApp | |
---|---|---|---|---|
HematologyREBLOZYL® | ||||
REBLOZYL® (luspatercept-aamt)Myelodysplastic Syndromes | ||||
Myelodysplastic | ||||
Beta-Thalassemia | ||||
Beta-Thalassemia |
luspatercept-aamt | ||||
Myelodysplastic Syndromes | ||||
Myelodysplastic | ||||
Beta-Thalassemianon-transfusion dependent | ||||
Beta-Thalassemianon-transfusion dependent | ||||
Myelofibrosis | ||||
Myelofibrosis |
* Bristol Myers Squibb-sponsored